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Abstract
Bipolar disorder is characterized by alternating episodes of mania and extreme
depression. Compounds such as omega-3 fatty acids and valproate individually treat symptoms
of bipolar disorder, one of which is elevated inositol levels. Lithium and valproate are known to
reduce inositol levels. The goal of this project is to combine linoleic acid (an omega-3 fatty acid
substitute) with valproate and observe the prodrug’s effects on the inositol biosynthetic pathway
using Saccharomyces cervisiae yeast as the model system. Since inositol is required for growth,
the effects of the prodrug on the inositol biosynthetic pathway was determined by comparing its
impact on the growth of wild type yeast cells and yeast cells that overproduce or lack the
production of inositol.
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Background
Bipolar disorder was originally known as manic-depressive insanity. It is distinguished
from other mood disorders based upon whether or not there are varying stages of mania or
elevated mood and depression. It affects 1-2% of the population (Vaden, et al. 2001). There are
many drugs that are currently used to treat bipolar disorder such as lithium, valproate,
antidepressants and recently omega-3 fatty acids.
Valproate is a mood stabilizer and one of the ways in which this compound may function
is through its interaction with the inositol biosynthetic pathway. Similar to lithium, valproate
targets certain parts of the pathway and lowers the levels of inositol, though by a different
mechanism (Vaden, et.al 2001). Inositol provides the basis of the formation of many second
messengers in the body. Second messengers themselves have a significant role in relaying
signals from outside the cell as they bind to receptors to inside the cell. Signals come from
various sources and once the signal reaches the inside of the cell via a second messenger, it
prompts a change in cell activity. Omega-3 fatty acids are still currently under research and the
mechanism as to how they affect the pathway is yet unknown. These fatty acids are used as a
supplement to bipolar disorder treatments.
Because valproate and omega-3 fatty acids are known to individually lower inositol
levels, this project seeks to determine what would happen if they were combined. It is unknown
whether or not the inositol levels would decrease, stay the same or increase. A plausible
hypothesis could be that the prodrug would work to lower the levels of inositol in a given
system. For the purposes of this project, specifically, an omega-3 fatty acid substitute (linoleic
acid, an essential fatty acid used as it is much less expensive) would be combined with valproate
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via mixed anhydride methodology. This method combines the two compounds with covalent
enzymatically-cleavable acylal linkages. Essentially during the organic synthesis portion,
valproate will be added to the linoleic starting material resulting in a valproate fatty acid prodrug
in the form of an oil.
In this project, Saccharomyces cerevisiae (strain SM7) yeast was used as the model
system with its inositol biosynthetic pathway being of primary concern. Yeast is easy to culture
and the inositol biosynthetic pathway is similar in both yeast and humans. A wild type strain as
well as two mutant strains was used. One of the mutant strains had a mutation that causes the
yeast to overproduce inositol and thus was called the “overproducer mutant”. The wild type and
this overproducer mutant were both grown in media that lacks any inositol as each of the strains
has to ability to synthesize inositol on its own. The other mutant strain had a mutation that causes
an underproduction of inositol and thus was called the “underproducer mutant”. Because it
synthesizes so little inositol it was grown in a media with a small amount of inositol in order to
see any growth at all. Yeast growth is dependent upon the production of inositol and thus based
upon the number of colonies that grow after the drug is applied, one was able to determine the
effects of the prodrug on the inositol biosynthetic pathway.

Methodology
PART ONE: ORGANIC SYNTHESIS
Trial 1:
A dry 50 mL round bottom flask with a spin vane was dried in the oven for 20 minutes
and then was cooled in an ice bath for 5 minutes. The flask was capped with a CaCl2 drying tube
and placed over a magnetic stir plate. Cyclohexane, linoleic acid and thionyl chloride were added
to the flask. The drying tube was replaced with a water-cooled condenser and the contents of the
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flask were refluxed for 60 minutes. After reflux, it was cooled to room temperature and the
drying tube was placed back onto the flask. Sodium valproate was added to the flask and stirred
at room temperature for 30 minutes. After this time, propanal and zinc oxide were added to the
flask and stirred at room temperature for 180 minutes.1 The solution was then added to a
separatory funnel. 25 mL of water was added and the solution was extracted 3 times with 20 mL
of CH2Cl2 each time. 20 mL of NaCl was added to remove the emulsion of the solution. The
organic portion of the solution was collected in a beaker and was dried with approximately 3
scoops of a spatula of Na2SO4 and gravity filtered by pouring the solution through filter lined
with filter paper. The solution was then rotovapped to evaporate the liquid solvent from the
desired oil product. Infrared (IR) spectroscopy and nuclear magnetic resonance (NMR) was
performed to analyze the product. Table 1 provides the amount of materials used in the first trial
of this experiment.
Table 1
Reagents
Linoleic Acid
Thionyl
Chloride
Sodium
Valproate
Propanal
Zinc Oxide
Cyclohexane

Molecular
Weight
(g/mol)
280.45
118.97

Density
(g/cm3)

Moles

Grams

Volume (mL)

0.9
1.638

0.0046
0.0079

-------------

1.42
0.574

166.20

--------

0.0046

0.765

--------

60.10
81.408
84.16

0.81
5.606
0.779

0.0046
0.00046
-------

------0.08
-------

0.341
15

Trial 2:
The procedure for trial 2 is identical to the first trial with a few exceptions. One of these
exceptions were that new, fresh propanal was used in hopes of removing some of the supposed
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  This period of time is twice as long as intended. However, the analysis showed that this
extended period of stirring did not affect the final product.
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impurities that resulted in the spectroscopy of the first trial. Another exception was that the
period of time when the solution was being stirred after the propanal and the zinc oxide were
added changed from 180 minutes to 90 minutes, the latter period of time being the original
amount of time that it should have been stirred. Table 1 provides again the amount of materials
used in this trial.
PART TWO: BIOLOGICAL TESTING
Trial 1:
Two types of liquid media were prepared using the ingredients in Table 2. The difference
between the two types of media was that one had inositol (I+) and the other did not (I-). 500 mL
of each media was prepared using two 1-liter Erlenmeyer flasks. YPD agarose gel plates were
also prepared using the ingredients in Table 3. The flasks with media were covered with
aluminum foil and autoclaved for 25-30 minutes along with three empty 250 mL Erlenmeyer
flasks. After autoclaving 100 mL of the I+ media was added to one of the 250 mL flasks and the
other two flasks were filled with 100 mL each of the I- media. The flask with the I+ media was
inoculated with plated SMY7 underproducer mutant yeast cells. One of the flasks with the Imedia was inoculated with plated SMY7 wildtype yeast cells and the remaining flask was
inoculated with plated SMY7 overproducer mutant yeast cells. These three flasks were then
placed in a shaker bath (150 rpm; 30 °C) for 24-30 hours to allow growth of the cells. After this
period of time, cell growth was estimated. To determine the effect of the prodrug on growth,
cells from these cultures were then used to inoculate media containing the prodrug. Equating the
O.D. reading of the spectrophotometer to cell concentration, cell cultures were inoculated to a
staring O.D. of 0.1.
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Trial 2:
The same procedure was used with the same concentration of the prodrug.
Table 2
Ingredient
Vitamin Free Yeast Base
Ammonium sulfate
Glucose
100x vitamins
Myo-inositol
Adenine
Arginine
Histidine
Leucine
Lysine
Methionine
Threonine
Tryptophan
Uracil
Deionized H2O

Amount
0.345 mL
1.005 mL
10 g
10 g
5 mL
7.5 mL
1 mL
1 mL
2 mL
1 mL
1 mL
8 mL
1 mL
8 mL
500 mL

Ingredient
Yeast extract
Bacto-peptone
Glucose
Agar
Deionized H2O

Amount
10 g
20 g
20 g
20 g
1L

Table 3

Results
PART ONE: ORGANIC SYNTHESIS
IR and NMR Analysis
Table 4 lists the important spectral features of the product as well as comments as shown by the
IR, the 1H NMR and the 13C NMR spectroscopy. Though there were two trials the results for the
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spectroscopy came out to be essentially the same revealing that an identical product was
synthesized for both products.
Table 4
Compounds

Linoleic Acid

IR (cm-1)
C-H2
(3009.63)
C-H3
(2927.23)
O=C-OH
(1710.69)

Propanal
-------

Valproate Fatty Acid
Product

C-H3
(2854.85)
O-C=O
(1760.78)
O-C=O
(1708.12)

1

H NMR

Ha (5.35)
Hb (0.9)
Hc (2.5)

Hd (9.75)
He (2.4)
Hf (1.1)

Hg (6.38)

1

H NMR
Comments
Ha = H’s
bonded to diene
carbons
Hb = methyl
group H’s at
opposite end of
the acid
Hc = alpha H’s
next to
carbonyl
Hd = H
attached to
carbonyl
He = alpha H’s
Hf = methyl
group H’s
Hg = H bonded
to carbon that
is single
bonded to two
oxygens
*Disappearance
of the Hd peak
(aldehyde
peak)

13

13

C NMR

C NMR
Comments

C1 = acid
carbon
C2 = diene
carbons

C1 (180.0)
C2 (130.0)

-------

None was
performed

C3 (77.0)
C4 (26.0)

Cannot say
conclusively

PART TWO: BIOLOGICAL TESTING
Table 5 displays results from Trial 1:
Table 5
Type of Media
Wild Type (without Prodrug)
Wild Type (with Prodrug 5mM)
Overproducer Mutant (without Prodrug)
Overproducer Mutant (with Prodrug 5mM)

Number of Colonies
401
0
4500
2
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Underproducer Mutant (without Prodrug)
Underproducer Mutant (with Prodrug 5mM)

180
0

Table 6 displays results from Trial 2:
Table 6
Type of Media
Wild Type (without Prodrug)
Wild Type (with Prodrug 5mM)
Overproducer Mutant (without Prodrug)
Overproducer Mutant (with Prodrug 5mM)
Underproducer Mutant (without Prodrug)
Underproducer Mutant (with Prodrug 5mM)

Number of Colonies
780
0
1000000 +
8
769
0

Discussion
PART ONE: PRODRUG SYNTHESIS
Linoleic acid was used instead of an actual omega-3 fatty acid because it is a less
expensive alternative that has a similar structure. The results of the synthesis in trial 1 proved to
be somewhat successful. Though the solution was stirred at one point for twice as long as it was
meant to (180 minutes instead of 90 minutes) this did not have an effect on the synthesis of the
product and still yielded a decent amount of the product. The structure of the product from trial 1
showed a similar structure to the desired product but the analysis had evidence of some impurity.
There were more peaks than should be seen at some points of the analysis. This was thought to
be because one of the starting materials, propanal, was decomposing and not very fresh. Thus the
main difference between the two trials was the use of fresher, newly ordered propanal for the
second trial. The second trial was successful as well with a good percent yield. However, the
results of the analysis when compared with the analysis of the first trial proved that the two
products were essentially the same and that the use of newer propanal had little to no effect.
IR and NMR Analysis
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The IR of the product differed from the IR of the starting material linoleic acid in that the

COOH peak that is indicative of an acid was missing. This peak was found at 1710.69 cm-1 on
the linoleic acid IR. The product also had two peaks at 1760.78 cm-1 and 1708.12 cm-1. These
peaks are characteristic of esters (O-C=O) and this change from an acid to an ester was exactly
what was desired. The 1H NMR of the product showed evidence of a hydrogen that is bonded to
a carbon single bonded to two oxygens (6.38 ppm). This as well as the disappearance of the
aldehyde peak (which was at 9.75 ppm and came from the starting material propanal) also helped
to verify that obtained the desired product was obtained. However, not all of the hydrogens of the
product could be seen on the 1H NMR. The 13C NMR of the linoleic acid showed the diene
carbons and the carbon of the acid portion. Although one is able to identify peaks on the product
13

C NMR, nothing can be said conclusively as to what product was formed.

PART TWO: BIOLOGICAL SYNTHESIS
Trials 1 and 2 (as shown in tables 5 and 6) exhibited essentially the same results and do
not support the hypothesis that the prodrug will inhibit the inositol biosynthetic pathway. One
would expect the overproducer with the prodrug to grow much more than just a small number of
colonies. It seems that the prodrug simply inhibits growth. The controls for the three types of
yeast for these two trials grew as expected. The overproducer mutant plate had the greatest
number of colonies as it produces the most inositol; the wildtype plate had an intermediate
number of colonies and the underproducer mutant plate at the smallest number of colonies on the
plate as it produces very little inositol. The variables with, in this case, the 5mM concentration of
the drug also showed satisfactory results. The prodrug inhibited growth of the wildtype and the
underproducer mutant altogether while the overproducer mutant, whose mutation causes the
yeast to grow profusely, a small number of colonies: 2 and 8, respectively for trials 1 and 2.
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Conclusion
For trials 1 and 2, a 5mM concentration of the prodrug completely stopped the growth of
the underproducer and the wildtype but not of the overproducer. This could suggest that a 5mM
concentration is effective in stopping the growth of yeast but this concentration was not too
strong to completely inhibit all yeast growth and it is not terribly weak as to allow the growth of
some wild type colonies. However, only one concentration was tested and one cannot say
conclusively what the effects of the prodrug on the inositol biosynthetic pathway are. Future
work must be completed including the testing of a second concentration (2.5mM) simultaneously
with the 5mM concentration.
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